RxDoctor Payments Data

Bay-Ink-Raine Falter

Family · Las Vegas, NVNPI 1295325785

Payments from drug & device makers

$6,342in general payments, 2019–2025

Across 20 payments — averaging $317.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$6K
  • Merz North America, Inc.$386
  • Organon$60
  • AbbVie$46
  • Bayer$35
  • E.r. Squibb & Sons, L.L.C.$28
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$86214%
  • Other$5,48086%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,342 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$684,430
Medicare patients
346
Services billed
16,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl556$530,719
FarxigaDapagliflozin Propanediol85$120,758
RestasisCyclosporine78$114,577
GemtesaVibegron85$110,003
EliquisApixaban75$107,213
LinzessLinaclotide62$84,764
ProliaDenosumab43$70,572
KerendiaFinerenone44$69,149
JardianceEmpagliflozin45$67,398
RybelsusSemaglutide26$63,348
OzempicSemaglutide31$53,710
SymbicortBudesonide/Formoterol Fumarate77$47,390
JanuviaSitagliptin Phosphate20$29,007
VemlidyTenofovir Alafenamide17$23,255
TradjentaLinagliptin13$18,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Linzess$46$199,341140 claims
BayerKerendia$35$69,14944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →